OVID vs. ATOS, GBIO, OMER, RENB, RIGL, GALT, MACK, TRVI, GTHX, and LFCR
Should you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include Atossa Therapeutics (ATOS), Generation Bio (GBIO), Omeros (OMER), Renovaro (RENB), Rigel Pharmaceuticals (RIGL), Galectin Therapeutics (GALT), Merrimack Pharmaceuticals (MACK), Trevi Therapeutics (TRVI), G1 Therapeutics (GTHX), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical preparations" industry.
Atossa Therapeutics (NASDAQ:ATOS) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, community ranking, analyst recommendations and institutional ownership.
Ovid Therapeutics received 116 more outperform votes than Atossa Therapeutics when rated by MarketBeat users. Likewise, 70.49% of users gave Ovid Therapeutics an outperform vote while only 64.96% of users gave Atossa Therapeutics an outperform vote.
In the previous week, Ovid Therapeutics had 5 more articles in the media than Atossa Therapeutics. MarketBeat recorded 9 mentions for Ovid Therapeutics and 4 mentions for Atossa Therapeutics. Atossa Therapeutics' average media sentiment score of 0.79 beat Ovid Therapeutics' score of 0.50 indicating that Ovid Therapeutics is being referred to more favorably in the news media.
Atossa Therapeutics has a net margin of 0.00% compared to Atossa Therapeutics' net margin of -13,351.53%. Ovid Therapeutics' return on equity of -31.01% beat Atossa Therapeutics' return on equity.
12.7% of Atossa Therapeutics shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 7.8% of Atossa Therapeutics shares are owned by company insiders. Comparatively, 13.3% of Ovid Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Atossa Therapeutics has higher earnings, but lower revenue than Ovid Therapeutics. Atossa Therapeutics is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.
Atossa Therapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.
Atossa Therapeutics currently has a consensus price target of $4.50, indicating a potential upside of 166.27%. Ovid Therapeutics has a consensus price target of $8.08, indicating a potential upside of 165.03%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Atossa Therapeutics is more favorable than Ovid Therapeutics.
Summary
Ovid Therapeutics beats Atossa Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Ovid Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ovid Therapeutics Competitors List
Related Companies and Tools
